64Cu-CB-TE2A-AR06 was rapidly accumulated by prostate cancer and cleared much slower from the tumors than from normal organs, suggesting that the high tumor uptake of GRPR ligands and the low intestinal and kidney uptake of GRPR antagonists make these compounds particularly attractive for peptide receptor-targeted radiotherapy (PRRT). This evidence concerns the gene GRPR and prostate carcinoma.